43 completed, 14 terminated, 13 recruiting, 6 unknown. 86 Phase 2, 21 Phase 1, 3 Phase 3.
Follow Fibrosarcoma: new trials by email Literature Review of Fibrosarcoma trials Research Report on Fibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor) | Phase 2 | Not yet recruiting | Girish Dhall, MD | 25 | 2027-01-01 | 2026-10-28 |
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1 | Phase 2 | Recruiting | University of Alabama at Birmingham | 41 | 2026-08-04 | 2026-08-24 |
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans Toripalimab, Anlotinib, Standard Chemotherapy - Dermatofibrosarcoma Protuberans (DFSP) | Phase 2 | Not yet recruiting | Yanjie Zhang, MD | 20 | 2026-06-15 | 2026-06-16 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| SPEARHEAD-3 Pediatric Study Afamitresgene autoleucel - Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) | Phase 1 / Phase 2 | Recruiting | USWM CT, LLC | 20 | 2023-09-01 | 2026-08-11 |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors Selinexor - Wilms Tumor, Rhabdoid Tumor | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2023-08-01 | 2026-10-23 |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors TNG462, Pembrolizumab - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 225 | 2023-05-26 | 2026-09-08 |
| Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors TNG908 - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Tango Therapeutics, Inc. | 110 | 2022-03-23 | 2026-04-15 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis AL2846 capsules - Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 22 | 2021-09-07 | 2024-03-21 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Tazemetostat in Malignant Peripheral Nerve Sheath Tumors Tazemetostat - Peripheral Nerve Sheath Tumor | Phase 2 | Active not recruiting | University of Florida | 10 | 2021-08-25 | 2026-06-04 |
Showing 20 of 86. Sign in to see all of them.
Sarcoma (60) · Neurofibrosarcoma (57) · Leiomyosarcoma (41) · Histiocytoma, Malignant Fibrous (37) · Liposarcoma (36) · Sarcoma, Synovial (35) · Hemangiosarcoma (28) · Dermatofibrosarcoma (26) · Rhabdomyosarcoma (25) · Sarcoma, Alveolar Soft Part (17) · Osteosarcoma (13) · Hemangiopericytoma, Malignant (12) · Malignant mesenchymal tumor (12) · Desmoplastic Small Round Cell Tumor (10)
Neoplasms by Histologic Type (86) · Neoplasms, Connective Tissue (86) · Neoplasms, Fibrous Tissue (86) · Neoplasms, Connective and Soft Tissue (85) · Neoplasms (84) · Neoplasms, Nerve Tissue (63) · Nervous System Diseases (59) · Nervous System Neoplasms (59) · Neurofibroma (57) · Neuromuscular Diseases (57) · Peripheral Nervous System Diseases (57) · Peripheral Nervous System Neoplasms (56) · Nerve Sheath Neoplasms (53) · Neoplasms, Muscle Tissue (48)
Doxorubicin (10) · Imatinib Mesylate (9) · Ifosfamide (7) · pazopanib (6) · Etoposide (4) · Filgrastim (4) · Radiotherapy (4) · Sirolimus (4) · pembrolizumab (4) · AZD 6244 (3) · Dactinomycin (3) · Docetaxel (3) · Gemcitabine (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Bevacizumab (2)
National Cancer Institute (NCI) (11) · European Organisation for Research and Treatment of Cancer - EORTC (8) · Memorial Sloan Kettering Cancer Center (7) · Sarcoma Alliance for Research through Collaboration (6) · Novartis Pharmaceuticals (3) · Oslo University Hospital (3) · Brown University (2) · Children's Oncology Group (2) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · SWOG Cancer Research Network (2) · Tango Therapeutics, Inc. (2) · AeRang Kim (1) · Alexander Z. Wei, MD (1) · Ankit Mangla, MD (1) · Ascentage Pharma Group Inc. (1)
United States (58) · France (9) · United Kingdom (7) · Belgium (6) · Canada (6) · Germany (5) · Netherlands (5) · Australia (4) · China (3) · Denmark (3) · Norway (3) · Poland (3) · Puerto Rico (3) · Spain (3) · Slovakia (2)
AeRang Kim, MD, PhD (3) · Brigitte C. Widemann, MD (2) · Brigitte Widemann, MD (2) · Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · Scott Schuetze, MD, PhD (2) · William Tap, MD (2) · Aaron R Weiss (1) · Alberto Chiappori, M.D. (1) · Alexander Wei, MD (1) · Allan T. van Oosterom, MD, PhD (1) · Ankit Mangla, MD (1) · Annabel B.M. Foot (1) · Anne B. Warwick, MD, MPH (1)
PMID 19451433, PMID 31401903, PMID 32827353, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 19088049, PMID 19451429, PMID 20338746, PMID 20471824, PMID 20932656, PMID 23382028, PMID 24215845, PMID 27502708, PMID 30410720, PMID 31969335, PMID 32089640, PMID 32554315, PMID 32702309, PMID 32956651, PMID 33362722, PMID 33882143, PMID 34321280, PMID 34380663, PMID 34515544, PMID 34716198, PMID 34722269, PMID 37523624, PMID 38243705, PMID 38358334, PMID 38579194, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39756156, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270
P30CA008748 (3), U10CA032102 (3), 2009 (2), N01CM62206 (2), U10CA098543 (2), U10CA180821 (2), U10CA180886 (2), N01CM62201 (1), N01CM62203 (1), P30CA012197 (1), P30CA016087 (1), P30CA033572 (1), R21CA117128 (1), U01CA069856 (1), U10CA031946 (1)